TABLE 2.
The response rates and survival outcomes stratified by different factors
| N | ORR | DCR | mPFS | (months) | mOS | (months) | |||
|---|---|---|---|---|---|---|---|---|---|
| Total | 69 | 23.2% | 46.4% | 1.9 | 95% CI: 1.6–2.1 | 8.9 | 95% CI: 6.6–11.2 | ||
| Baseline NLR | |||||||||
| ≥4 | 33 | 9.1% | 39.4% | 1.8 |
HR 1.79 (1.07–3.00) p = 0.026 |
7.4 |
HR 2.28 (1.24–4.17) p = 0.008 |
||
| <4 | 36 | 36.1% | p = 0.018 | 52.8% | p = 0.265 | 3.2 | 11.0 | ||
| V1‐NLR | |||||||||
| ≥4 | 32 | 15.6% | 40.6% | 1.8 | HR 1.74 (1.03–2.93) | 7.4 | HR 2.38 (1.26–4.50) | ||
| <4 | 32 | 34.4% | p = 0.083 | 59.4% | p = 0.134 | 3.6 | p = 0.037 | 11.5 | p = 0.007 |
| Variation of NLR from baseline to V1 | |||||||||
| ≥ −20% | 45 | 22.2% | 48.9% | 2.0 | HR 1.38 (0.81–2.34) | 7.9 | HR 1.85 (1.03–3.31) | ||
| < −20% | 19 | 31.6% | p = 0.430 | 52.6% | p = 0.784 | 2.4 | p = 0.231 | 14.0 | p = 0.038 |
| HLA‐I | |||||||||
| Homo | 11 | 0 | 9.1% | 1.8 |
HR 3.37 (1.35–8.46) p = 0.010 |
5.6 |
HR 3.97 (1.56–10.12) p = 0.004 |
||
| Hetero | 58 | 27.6% | p = 0.056 | 53.4% | p = 0.018 | 2.4 | 10.5 | ||
| PD‐L1 TPS | |||||||||
| ≥10% | 22 | 36.4% | 63.6% | 4.0 | HR 0.47 (0.28–0.79) | 8.3 | HR 0.96 (0.54–1.71) | ||
| <10% | 42 | 14.3% | p = 0.042 | 33.3% | p = 0.020 | 1.8 | p = 0.004 | 9.6 | p = 0.883 |
| PD‐L1 TPS ≥10% | |||||||||
| NLR ≥ 4 | 7 | 14.3% | 57.1% | 3.7 | HR 1.35 (0.51–3.61) | 4.0 | HR 2.89 (0.92–9.07) | ||
| NLR < 4 | 15 | 46.7% | p = 0.193 | 66.7% | p = 1.000 | 4.4 | p = 0.545 | 8.4 | p = 0.069 |
| Homo | 4 | 0 | 0 | 1.8 | HR 12.6 (1.88–84.46) | 3.8 | HR 11.53 (1.80–73.95) | ||
| Hetero | 18 | 44.4% | p = 0.254 | 77.8% | p = 0.010 | 4.7 | p = 0.009 | 9.8 | p = 0.010 |
| PD‐L1 TPS <10% | |||||||||
| NLR ≥ 4 | 24 | 8.3% | 29.2% | 1.7 | HR 1.43 (0.76–2.68) | 7.4 | HR 2.45 (1.08–5.54) | ||
| NLR < 4 | 18 | 22.2% | p = 0.408 | 38.9% | p = 0.508 | 1.9 | p = 0.265 | 11.0 | p = 0.032 |
| Homo | 6 | 0 | 16.7% | 1.7 | HR 2.32 (0.74–7.26) | 5.6 | HR 1.72 (0.59–5.00) | ||
| Hetero | 36 | 16.7% | p = 0.569 | 36.1% | p = 0.640 | 1.8 | p = 0.147 | 9.9 | p = 0.322 |
| NLR + HLA‐I | |||||||||
| Homo & NLR ≥ 4 | 4 | 0 | 0 | 1.4 | 1.8 | ||||
| Homo & NLR < 4 | 7 | 0 | 14.3% | 1.8 | 6.5 | ||||
| Hetero & NLR ≥ 4 | 29 | 10.3% | 44.8% | 1.8 | 8.2 | ||||
| Hetero & NLR < 4 | 29 | 44.8% | * p = 0.005 | 62.1% | * p = 0.023 | 4.1 | * p < 0.001 | 13.4 | * p < 0.001 |
Abbreviations: CI, confidence interval; DCR, disease control rate; hetero, heterozygosity; HLA‐I, human leukocyte antigen class I; homo, homozygosity; PD‐L1, programmed death receptor ligand 1; mOS, median overall survival; mPFS, median progression‐free survival; NLR, neutrophil to lymphocyte ratio; ORR, overall response rate; TPS, tumor proportion score; V1, first tumor evaluation.
*
The comparison among four subgroups.